Notable Mover: Egalet Corp Stock Price Declines Today

Notable Mover: Egalet Corp Stock Price Declines Today

The stock of Egalet Corp (NASDAQ:EGLT) is a huge mover today! The stock decreased 4.45% or $0.34 during the last trading session, hitting $7.3. About 466,686 shares traded hands or 45.69% up from the average. Egalet Corp (NASDAQ:EGLT) has risen 18.27% since March 2, 2016 and is uptrending. It has outperformed by 10.01% the S&P500.
The move comes after 8 months negative chart setup for the $185.59 million company. It was reported on Oct, 6 by Barchart.com. We have $6.57 PT which if reached, will make NASDAQ:EGLT worth $18.56 million less.

Analysts await Egalet Corp (NASDAQ:EGLT) to report earnings on November, 2. They expect $-0.87 EPS, down 7.41% or $0.06 from last year’s $-0.81 per share. After $-0.97 actual EPS reported by Egalet Corp for the previous quarter, Wall Street now forecasts -10.31% EPS growth.

According to Zacks Investment Research, “Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom.”

Insitutional Activity: The institutional sentiment decreased to 1.79 in Q2 2016. Its down 0.13, from 1.92 in 2016Q1. The ratio worsened, as 9 funds sold all Egalet Corp shares owned while 10 reduced positions. 16 funds bought stakes while 18 increased positions. They now own 13.97 million shares or 0.03% less from 13.98 million shares in 2016Q1.
Barclays Public Ltd reported 13,272 shares or 0% of all its holdings. Wells Fargo And Mn accumulated 0% or 1,471 shares. Federated Investors Incorporated Pa has 1.09M shares for 0.02% of their US portfolio. Teachers Advsrs holds 0% of its portfolio in Egalet Corp (NASDAQ:EGLT) for 36,318 shares. Tiaa Cref Management Limited Co accumulated 0% or 75,445 shares. Rhumbline Advisers accumulated 25,267 shares or 0% of the stock. The Pennsylvania-based Janney Montgomery Scott Limited Liability has invested 0.01% in Egalet Corp (NASDAQ:EGLT). Broadfin Cap Ltd Liability Company accumulated 1.13 million shares or 0.55% of the stock. Blackrock last reported 0% of its portfolio in the stock. The Pennsylvania-based Brandywine Global Inv Management Lc has invested 0% in Egalet Corp (NASDAQ:EGLT). Summit Group Inc Ltd Limited Liability Company accumulated 0.03% or 10,636 shares. Hightower Advisors Limited Liability Corporation holds 0.01% or 229,664 shares in its portfolio. Bnp Paribas Arbitrage has invested 0% of its portfolio in Egalet Corp (NASDAQ:EGLT). California Public Employees Retirement System last reported 0% of its portfolio in the stock. California State Teachers Retirement Systems accumulated 46,446 shares or 0% of the stock.

More important recent Egalet Corp (NASDAQ:EGLT) news were published by: Marketwatch.com which released: “Egalet Corp. NASDAQ: EGLT” on February 11, 2014, also Prnewswire.com published article titled: “Egalet Announces FDA Advisory Committee Meeting will Take Place August 4, 2016 …”, Prnewswire.com published: “Egalet Appoints Patrick Shea as Chief Commercial Officer” on September 19, 2016. More interesting news about Egalet Corp (NASDAQ:EGLT) was released by: Prnewswire.com and their article: “Egalet Completes $40 Million Secured Debt Financing” with publication date: August 31, 2016.

EGLT Company Profile

Egalet Corporation, incorporated on August 21, 2013, is a specialty pharmaceutical company. The Firm is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Firm is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s Guardian Technology is a polymer matrix tablet technology that utilizes a manufacturing process, injection molding, which results in tablets with controlled-release properties, as well as physical and chemical features that have been demonstrated to resist both common and rigorous methods of manipulation. The Company’s Guardian Technology can be used to create tablets. The Company’s Guardian Technology platform, which combines abuse-deterrent features and precision delivery, is applied across various classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients (APIs) with similar or different release profiles.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment